0001209191-16-142259.txt : 20160921 0001209191-16-142259.hdr.sgml : 20160921 20160921160759 ACCESSION NUMBER: 0001209191-16-142259 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160920 FILED AS OF DATE: 20160921 DATE AS OF CHANGE: 20160921 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ARCA biopharma, Inc. CENTRAL INDEX KEY: 0000907654 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 363855489 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 11080 CIRCLEPOINT ROAD STREET 2: SUITE 140 CITY: WESTMINSTER STATE: CO ZIP: 80020 BUSINESS PHONE: 720-940-2200 MAIL ADDRESS: STREET 1: 11080 CIRCLEPOINT ROAD STREET 2: SUITE 140 CITY: WESTMINSTER STATE: CO ZIP: 80020 FORMER COMPANY: FORMER CONFORMED NAME: NUVELO INC DATE OF NAME CHANGE: 20030203 FORMER COMPANY: FORMER CONFORMED NAME: HYSEQ INC DATE OF NAME CHANGE: 19970610 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ozeroff Christopher David CENTRAL INDEX KEY: 0001454996 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22873 FILM NUMBER: 161895721 MAIL ADDRESS: STREET 1: 8001 ARISTA PLACE STREET 2: SUITE 200 CITY: BROOMFIELD STATE: CO ZIP: 80021 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2016-09-20 0 0000907654 ARCA biopharma, Inc. ABIO 0001454996 Ozeroff Christopher David 11080 CIRCLEPOINT ROAD SUITE 140 WESTMINSTER CO 80020 0 1 0 0 S.V.P., General Counsel Common Stock 2016-09-20 4 S 0 1185 2.89 D 18400 D Represents shares of common stock sold pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person with respect to the vesting of previously reported Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's 2013 Amended and Restated Equity Incentive Plan (the "Plan") The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions ranged from $2.88 to $2.89. Upon request of the SEC staff, ARCA biopharma, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold at each separate price. Includes (i) remaining 2,443 previously reported shares issued as RSUs under the Plan that vest in two equal annual installments beginning on 2/27/17, and (ii) 2,290 previously reported shares issued as RSUs under the Plan that vest in two equal annual installments beginning 4/2/17, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined under the Plan; and 13,667 previously reported shares of common stock held directly. /s/ Christopher D. Ozeroff 2016-09-21